Compare Amphastar Pharmaceuticals Inc (AMPH) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Vanguard Ultra Short Bond ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Vanguard Ultra Short Bond ETF trades at $49.65. Which is the better fit depends on your goals.
| AMPH | VUSB | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $30.81 | $50.03 |
52-Week Low | $16.87 | $49.60 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
VUSB trades at $49.66 with minimal daily movement, showing a slight 0.01% gain. Technical indicators signal a bearish trend with moving averages in sell territory, though oscillators are neutral. The ETF offers a yield of approximately 4.35% and is positioned as a cash alternative amid a non-inverted yield curve, with recent dividends paid in mid-2026.
The outlook for VUSB is cautious due to bearish technicals and potential Fed rate increases in 2026, which could impact short-term bonds. Risks include interest rate sensitivity and credit/duration exposure, but the ETF remains a viable option for investors seeking yield above money-market funds with moderate risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
